Pictilisib
- Generic Name
- Pictilisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N7O3S2
- CAS Number
- 957054-30-7
- Unique Ingredient Identifier
- ICY00EMP8P
- Background
Pictilisib has been used in trials studying the treatment of Solid Cancers, Breast Cancer, Advanced Solid Tumours, Metastatic Breast Cancer, and Non-Hodgkin's Lymphoma, Solid Cancers, among others.
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-12-16
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 501
- Registration Number
- NCT01493843
- Locations
- 🇺🇸
Franklin Square Hospital, Baltimore, Maryland, United States
🇦🇺Royal Melbourne Hospital; Hematology and Medical Oncology, Parkville, Victoria, Australia
ðŸ‡ðŸ‡ºOrszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2016-12-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT00996892
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT00960960
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath